Colon cancer stem cells - From basic to clinical application

Cancer Letters

Volumn 338, Issue 1, 2013, Pages 127-140

  Botchkina, Galina ^a  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer stem cells; Colon cancer; CSC targeted therapies; Signaling pathways

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; ANTINEOPLASTIC AGENT; BETA CATENIN; BMI1 PROTEIN; CD133 ANTIGEN; CELL MARKER; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CURCUMIN; DOCETAXEL; FLUOROURACIL; G PROTEIN COUPLED RECEPTOR; HERMES ANTIGEN; KRUPPEL LIKE FACTOR 4; LIN 28; MYC PROTEIN; NOTCH RECEPTOR; OCTAMER TRANSCRIPTION FACTOR 4; PACLITAXEL; PEPTIDES AND PROTEINS; PROTEIN LGR5; PROTEIN MUSASHI1; SBT 1214; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR SOX9; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT PROTEIN;

ANTIGEN EXPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENICITY; CELL DIFFERENTIATION; CELL HETEROGENEITY; CELL POPULATION; CELL PROLIFERATION; CELL RENEWAL; CELL TYPE; CHEMOSENSITIVITY; COLON CANCER; DRUG EFFICACY; DRUG POTENTIATION; GENE EXPRESSION; GENOMICS; HUMAN; INTRACELLULAR SIGNALING; MESENCHYMAL STEM CELL; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEOMICS; RADIOSENSITIVITY; SHORT SURVEY; TREATMENT OUTCOME; TUMOR INITIATING CELL; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

EID: 84882902414     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.04.006     Document Type: Review

References (222)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Siegel R., Ward E., Brawley O., Jemal A. Cancer Statistics, 2011. CA. Cancer J. Clin. 2011, 61:212-236.
3. Dalerba P., Dylla S.J., Park I.K., Liu R., Wang X., Cho R.W., Hoey T., Gurney A., Huang E.H., Simeone D.M., Shelton A.A., Parmiani G., Castelli C., Clarke M.F. Phenotypic characterization of human colorectal cancer stem cells. PNAS 2007, 104:10158-10163.
4. Mimeault M., Hauke R., Mehra P.P., Batra S.K. Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J. Cell. Mol. Med. 2007, 11:981-1011.
5. Knoblich J.A. Mechanisms of asymmetric stem cell division. Cell 2008, 132:583-597.
6. Neumuller R.A., Knoblich J.A. Wicked views on stem cell news. Nat. Cell Biol. 2009, 11:678-679.
7. Wang H., Somers G.W., Bashirullah A., Heberlein U., Yu F., Chia W. Aurora-A acts as a tumor suppressor and regulates self-renewal of Drosophilia neuroblasts. Genes Dev. 2006, 20:3453-3463.
8. Gonzalez C. Spindle orientation, asymmetric division and tumour suppression in Drosophila stem cells. Nat. Rev. Genet. 2007, 8:462-472.
9. Castellanos E., Dominguez P., Gonzalez C. Centrosome dysfunction in Drosophila neural stem cells causes tumors that are not due to genome instability. Curr. Biol. 2008, 18:1209-1214.
10. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
11. Potten C.S., Morris R.J. Epithelial stem cells in vivo. J Cell Sci. Suppl. 1988, 10:45-62.
12. Sancho E., Batlle E., Clevers H. Signaling pathways in intestinal development and cancer. Annu. Rev. Cell Dev. Biol. 2004, 20:695-723.
13. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
14. Clarke M.F., Fuller M. Stem cells and cancer: two faces of eve. Cell 2006, 124:1111-1115.
15. Dingli D., Michor F. Successful therapy must eradicate cancer stem cells. Stem cells 2006, 24:2603-2610.
16. Kwon C., Cheng P., King I.N., Andersen P., Shenje L., Nigam V., Srivastava D. Notch post-translationally regulates β-catenin protein in stem and progenitor cells. Nat. Cell Biol. 2011, 13:1244-1251.
17. Barker N., Ridgway R.A., van Es J.H., van de Wetering M., Begthel H., van den Born M., Danenberg E., Clarke A.R., Sansom O.J., Clevers H. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009, 457:608-611.
18. Sell S. On the stem cell origin of cancer. Am. J. Pathol. 2010, 176:2484-2494.
19. J. Nautiyal, J. Du, Y. Yu, S.S. Kanwar, E. Levi, and A.P. Majumdar, EGFR regulation of colon cancer stem-like cells during aging and in response to the colonic carcinogen dimethylhydrazine. Am. J. Physiol. Gastrointest. Liver Physiol. Jan 26 (2012) Epub ahead of print.
20. Campbell L.L., Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution?. Cell Cycle 2007, 6:2332-2338.
21. Dick J.E. Stem cell concepts renew cancer research. Blood 2008, 112:4793-4807.
22. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., Minden M., Paterson B., Caligiuri M.A., Dick J.E. A cell initiating human acute myeloid leukaemia after transplanation into SCID mice. Nature 1994, 367:645-648.
23. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983-3988.
24. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8:755-768.
25. Schatton T., Frank N.Y., Frank M.H. Identification and targeting of cancer stem cells. BioEssays 2009, 31:1038-1049.
26. Mimeault M., Batra S.K. New advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrence. Histol. Histopathol. 2010, 25:1057-1073.
27. Zeki S.S., Graham T.A., Wright N.A. Stem cells and their implications for colorectal cancer. Nat. Rev. Gastroenterol. Hepatol. 2011, 8:90-100.
28. Wilson B.J., Schatton T., Frank M.H., Frank N.Y. Colorectal cancer stem cells: biology and therapeutic implications. Curr. Colorectal Cancer Rep. 2011, 7:128-135.
29. Malik B., Nie D. Cancer stem cells and resistance to chemo and radio therapy. Front Biosci. (Elite Ed) 2012, 4:2142-2149.
30. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63:5821-5828.
31. Collins A.T., Barry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65:10946-10951.
32. Bussolati B., Bruno S., Grange C., Buttiglieri S., Deregibus M.C., Cantino D., Camussi G. Isolation of renal progenitor cells from adult human kidney. Am. J. Pathol. 2005, 166:545-555.
33. + hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem. Biophys. Res. Commun. 2006, 351:820-824.
34. Yin S., Li J., Hu C., Chen X., Yao M. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int. J. Cancer 2007, 120:1444-1450.
35. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
36. O'Brien C.A., Pollett A., Gallinger S., Dick J. A human colon cancer cell capable of initiating tumor growth in immunodeficient mice. Nature 2007, 445:106-110.
37. Todaro M., Alea M.P., Stefano A.B., Cammareri P., Vermeulen L., Lovino F., Tripodo C., Russo A., Gulotta G., Medema J.P., Stassi G. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007, 1:389-402.
38. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., Bruns C.J., Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
39. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., Wicha M.S., Clarke M.F., Simeone D.M. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67:1030-1037.
40. Shmelkov S.V., St.Clair R., Lyden D., Rafii S. AC133/CD133/Prominin-1. Int. J. Biochem. Cell Biol. 2005, 37:715-719.
41. Kemper K., Sprick M.R., de Bree M., Scopelliti A., Vermeulen L., Hoek M., Zeilstra J., Pals S.T., Mehmet H., Stassi G., Medema J.P. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res. 2010, 70:719-729.
42. Green C.L., Loken M., Buck D., Deeg H.J. Discordant expression of AC133 and AC141 in patients with myelodysplastic syndrome (MDS) and acute myelogeneous leukemia (AML). Leukemia 2000, 14:770-772.
43. Ponta H., Sherman L., Herrlich P.A. CD44: from adhesion molecules to signalling regulators. Nat. Rev. Mol. Cell Biol. 2003, 4:33-45.
44. Marhaba R., Klingbeil P., Nuebel T., Nazarenko I., Buechler M.W., Zoeller M. CD44 and EpCAM: cancer-initiating cell markers. Curr. Mol. Med. 2008, 8:784-804.
45. Corbeil D., Röper K., Hellwig A., Tavian M., Miraglia S., Watt S.M., Simmons P.J., Peault B., Buck D.W., Huttner W.B. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J. Biol. Chem. 2000, 275:5512-5520.
46. Zhu L., Gibson P., Currie D.S., Tong Y., Richardson R.J., Bayazitov I.T., Poppleton H., Zakharenko S., Ellison E.S., Gilbertson R.J. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 2009, 457:603-607.
47. Snippert H.J., van Es J.H., van den Born M., Begthel H., Stange D.E., Barker N., Clevers H. Prominin-1/CD133 marks stem cells and early progenitors in mouse small intestine. Gastroenterology 2009, 136:2187-2194.
48. Arena V., Caredda E., Cufino V., Stigliano E., Scaldaferri F., Gasbarrini A., Cittadini A., Sgambato A. Differential CD133 expression pattern during mouse colon tumorigenesis. Anticancer Res. 2011, 31:4273-4275.
49. Du L., Wang H., He L. CD44 is of functional importance for colorectal cancer stem cells. Clin. Cancer Res. 2008, 14:6751-6760.
50. Joo M.Y., Tsai H.C., Glöckner S.C., Lin S., Ohm J.E., Easwaran H., James C.D., Costello J.F., Riggins G., Eberhart C.G., Laterra J., Vescovi A.L., Ahuja N., Herman J.G., Schuebel K.E., Baylin S.B. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res. 2008, 68:8094-8103.
51. Horst D., Kriegl L., Engel J., Kirchner T., Jung A. CD13 expression is an independent prognostic marker for low survival in colorectal cancer. Brit. J. Cancer 2008, 99:1285-1289.
52. Kojima M., Ishii G., Atsumi N., Fujii S., Saito N., Ochiai A. Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci. 2008, 99:1578-1583.
53. Shmelkov S.V., Butler J.M., Hooper A.T., Hormigo A., Kushner J., Milde T., Clair R.St., Baljevic M., White I., Jin D.K., Chadburn A., Murphy A.J., Valenzuela D.M., Gale N.W., Thurston G., Yancopoulos G.D., D'Angelica M., Kemeny N., Lyden D., Rafii S. CD133 expression is not restricted to stem cells, and both CD133 and CD133 metastatic colon cancer cells initiate tumors. J. Clin. Invest. 2008, 118:2111-2120.
54. Beier D., Hau P., Proescholdt M., Lohmeier A., Wishhusen J., Oefner P.J., Aigner L., Brawanski A., Bogdahn U., Beier C. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007, 67:4010-4015.
55. Wang J., Sakariassen P.Ø., Tsinkalovsky O., Immervoll H., Bøe S.O., Svendsen A., Prestegarden L., Rosland G., Thorsen F., Stuhr L., Molven A., Bjerkvig R., Enger P.Ø. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int. J. Cancer 2008, 122:761-768.
56. Navarro-Alvarez N., Kondo E., Kawamoto H., Hassan W., Yuasa T., Kubota Y., Seita M., Nakahara H., Hayashi T., Nishikawa Y., Hassan R.A., Javed S.M., Noguchi H., Matsumoto S., Nakaji S., Tanaka N., Kobayashi N., Soto-Gutierrez A. Isolation and propagation of a human CD133-negative colon tumor derived cell line with tumorigenic and angiogenic properties. Cell Transplant 2010, 19:865-877.
57. Karbanová J., Missol-Kolka E., Fonseca A.V., Lorra C., Janich P., Hollerová H., Jászai J., Ehrmann J., Kolár Z., Liebers C., Arl S., Subrtová D., Freund D., Mokry J., Huttner W.B., Corbeil D. The stem cell marker CD133 (Prominin-1) is expressed in various human glandular epithelia. J. Histochem. Cytochem. 2008, 56:977-993.
58. Immervoll H., Hoem D., Sakariassen P.Ø., Steffensen O.J., Molven A. Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer 2008, 8:48-61.
59. Yang Z.L., Zheng Q., Yan J., Pan Y., Wang Z.C. Upregulated CD133 expression in tumorigenesis of colon cancer cells. World J. Gastroenterol. 2011, 17:932-937.
60. Mélin C., Perraud A., Akil H., Jauberteau M.O., Cardot P., Mathonnet M., Battu S. Cancer stem cell sorting from colorectal cancer cell lines by sedimentation field flow fractionation. Anal. Chem. 2012, 84:1549-1556.
61. Elsaba T.M., Martinez-Pomares L., Robins A.R., Crook S., Seth R., Jackson D., McCart A., Silver A.R., Tomlinson I.P., Ilyas M. The stem cell marker CD133 associates with enhanced colony formation and cell motility in colorectal cancer. PLoS One 2010, 5:e10714.
62. Botchkina G.I., Zuniga E.S., Das M., Wang Y., Wang H., Zhu S., Savitt A.G., Rowehl R.A., Leyfman Y., Ju J., Shroyer K., Ojima I. New-generation toxoid SB-T-1214 inhibits stem cell-related gene expression in 3D cancer spheriods induced by purified colon tumor-initiating cells. Mol. Cancer 2010, 9:192-204.
63. Yeung T.M., Gandhi S.C., Wilding J.L., Muschel R., Bodmer W.F. Cancer stem cells from colorectal cancer-derived cell lines. Proc. Natl. Acad. Sci. USA 2010, 107:3722-3727.
64. Ieta K., Tanaka F., Haraguchi N., Kita Y., Sakashita H., Minori K., Matsumoto T., Inoue H., Kuwano H., Mori M. Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann. Surg. Oncol. 2008, 15:638-648.
65. Vermeulen L., Todaro M., de Sousa Mello F., Sprick M.R., Kemeny N., Perez Alea M., Richel D.J., Stassi G., Medema J.P. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc. Natl. Acad. Sci. USA 2008, 105:13427-13432.
66. + population efficiently enriches colon cancer initiating cells. Ann. Surg. Oncol. 2008, 15:2927-2933.
67. Rowehl R.H., Crawford H., Dufour A., Leyfman Y., Ju J., Botchkina G.I. Genomic analysis of prostate cancer stem cells isolated from highly metastatic cell line. Cancer Genomics Proteomics 2008, 5:301-309.
68. Botchkina I.L., Rowehl R.A., Rivadeneira D.E., Karpeh M.S.J., Crawford H., Dufour A., Ju J., Weng Y., Leyfman Y., Botchkina G.I. Phenotypic subpopulations of metastatic colon cancer stem cells. Cancer Genomics Proteomics 2009, 6:19-30.
69. Taïeb N., Maresca M., Guo X.J., Garmy N., Fantini J., Yahi N. The first extracellular domain of the tumour stem cell marker CD133 contains an antigenic ganglioside-binding motif. Cancer Lett. 2009, 278:164-173.
70. Fargeas C.A., Karbanová J., Jászai J., Corbeil D. CD133 and membrane microdomains: old facets for future hypotheses. World J. Gastroenterol. 2011, 17:4149-4152.
71. Jahn K.A., Su Y., Braet F. Multifaceted nature of membrane microdomains in colorectal cancer. World J. Gastroenterol. 2011, 17:681-690.
72. Yu Y., Flint A., Dvorin E.L., Bischoff J. AC133-2, a novel isoform of human AC133 stem cell antigen. J. Biol. Chem. 2002, 277:20711-20716.
73. Yan K.S., Chia L.A., Li X., Ootani A., Su J., Lee J.Y., Su N., Luo Y., Heilshom S.C., Amieva M.R., Sangiorgi E., Capecchi M.R., Kuo C.J. The intestinal stem cell markers Bmi1 and Lgr5 identify two functionally distinct populations. Proc. Natl. Acad. Sci. USA 2012, 109:466-471.
74. Dieter S.M., Ball C.R., Hoffmann C.M., Nowrouzi A., Herbst F., Zavidij O., Abel U., Arens A., Weichert W., Brand K., Koch M., Weitz J., Schmidt M., von Kalle C., Glimm H. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 2011, 9:357-365.
75. Quintana E., Shackleton M., Sabel M.S., Fullen D.R., Johnson T.M., Morrison S.J. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598.
76. Gisina A.M., Lupatov A.Y., Karalkin P.A., Mainovskaya O.A., Petrov L.O., Sidorov D.V., Yarygin V.N., Yarygin K.N. Detection of minor subpopulations of colorectal adenocarcinoma cells expressing cancer stem cell markers. Bull. Exp. Biol. Med. 2011, 151:234-238.
77. Sneige N., Kemp B., Pusztai L., Asmar L., Hortobagyi G.N. Chemotherapy-induced histologic changes in mastectomy specimens and their potential significance. Breast 2001, 10:492-500.
78. Weihua Z., Lin Q., Ramoth A.J., Fan D., Fidler I.J. Formation of solid tumors by a single multinucleated cancer cell. Cancer 2011, 117:4092-4099.
79. Staelens L., Van Poppel H., Vanuytsel L., Van Oosterom A., Van Damme B., Baert L. Sarcomatoid renal cell carcinoma: case report and review of the literature. Acta Urol. Belg. 1997, 65:39-42.
80. + cancer stem cells in glioblastoma. Mol. Cancer 2006, 5:67.
81. Zeppernick F., Ahmadi R., Campos B., Dictus C., Helmke B.M., Becker N., Lichter P., Unterberg A., Radlwimmer B., Herold-Mende C.C. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin. Cancer Res. 2008, 14:123-129.
82. Maeda S., Shinchi H.H., Kurahara H.Y., Mataki Y., Maemura K., Sato M., Natsugoe S., Aikou T., Takao S.S. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Brit. J. Cancer 2008, 98:1389-1397.
83. Wang L.M., Kevans D., Mulcahy H., O'Sullivan J., Fennelly D., Hyland J., O'Donoghue D., Sheahan K. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am. J. Surg. Pathol. 2009, 33:134-141.
84. Mehra N., Penning M., Maas J., Beerepoot L.V., van Daal N., van Gils C.H., Giles R.H., Voest E.E. Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases. Clin. Cancer Res. 2006, 12:4859-4866.
85. Lin E.H., Hassan M., Li Y., Zhao H., Nooka A., Sorenson E., Xie K., Champlin R., Wu X., Li D. Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Cancer 2007, 110:534-542.
86. Pohl A., El-Khoueiry A., Yang D., Zhang W., Lurje G., Ning Y., Winder T., Hu-Lieskoven S., Iqbal S., Danenberg K.D., Kahn M., Teo J.L., Shriki J., Stebbing J., Lenz H.J. Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy. Pharmacogenom. J. 2012, (January 10):1-8.
87. Wakamatsu Y., Sakamoto N., Oo H.Z., Naito Y., Uraoka N., Anami K., Sentani K., Oue N., Yasui W. Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. Pathol. Int. 2012, 62:112-119.
88. Pilati P., Mocellin S., Bertazza L., Galdi F., Briarava M., Mammano E., Tessari E., Zavagno G., Nitti D. Prognostic value of putative circulating cancer stem cells in patients undergoing hepatic resection for colorectal liver metastasis. Ann. Surg. Oncol. 2011, 19:402-408.
89. Bao S., Wu Q., Sathornsumetee S., Hao Y., Li Z., Hjelmeland A.B., Shi Q., McLendon R.E., Bigner D.D., Rich J.N. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006, 66:7843-7848.
90. + renal progenitor cells contribute to tumor angiogenesis. Am. J. Pathol. 2006, 169:2223-2235.
91. Wong R.S.Y. Mesenchymal stem cells: angels or demons?. J. Biomed. Biotechnol. 2011, 2011:1-8.
92. Lazennec G., Jorgensen C. Concise review: adult multipotent stromal cells and cancer: risk or benefit?. Stem Cells 2008, 26:1387-1394.
93. Ogawa H., Iwaya K., Izumi M., Kuroda M., Serizawa H., Koyanagi Y., Mukai K. Expression of CD10 by stromal cells during colorectal tumor development. Hum. Pathol. 2002, 33:806-811.
94. Cui L., Ohuchida K., Mizumoto K., Moriyama T., Onimaru M., Nakata K., Nabae T., Ueki T., Sato N., Tominaga Y., Tanaka M. Prospectively isolated cancer-associated CD10(+) fibroblasts have stronger interactions with CD133(+) colon cancer cells than with CD133(-) cancer cells. PLoS One 2010, 5:e12121.
95. Kleivi K., Lind G.E., Diep C.B., Meling G.I., Brandal L.T., Nesland J.M., Myklebost O., Rognum T.O., Giercksky K.E., Skotheim R.I., Lothe R.A. Gene expression profiles of primary colorectal carcinomas, livermetastases, and carcinomatoses. Mol. Cancer 2007, 6:2.
96. Jimenez C.R., Knol J.C., Meijer G.A., Fijneman R.J.A. Proteomics of colorectal cancer: overview of discovery studies and identification of commonly identified cancer-associated proteins and candidate CRC serum markers. J. Proteomics 2010, 73:1873-1895.
97. O'Dwyer D., Ralton L.D., O'Shea A., Murray G.I. The proteomics of colorectal cancer: identification of a protein signature associated with prognosis. PLoS One 2011, 6:e27718.
98. - epithelial cells from human prostate. Prostate 2008, 68:1007-1024.
99. Glinsky G.V. "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management. J. Clin. Oncol. 2008, 26:2846-2853.
100. Zou J., Zou P., Lou Y., Xiao Y., Wang J., Liu L. The cross-talk between ROS and p38MAPKα in the ex vivo expanded human umbilical cord blood CD133(+) cells. J. Huazhong Univ. Sci. Technol. Med. Sci. 2011, 31:591-595.
101. Evans C.A., Glen A., Eaton C.L., Larre S., Catto J.M.F., Hamdy F.C., Wright P.C., Rehman I. Prostate cancer proteomics: the urgent need for clinically validated biomarkers. Proteom. Clin. Appl. 2009, 3:197-212.
102. Fang S.H., Guidroz J.A., O'Malley Y., Lal G., Sugg S.L., Howe J.R., Jensen C.S., Weigel R.J. Expansion of a cell population expressing stem cell markers in parathyroid glands from patients with hyperparathyroidism. Ann. Surg. 2010, 251:101-113.
103. Larkin S.E., Zeidan B., Taylor M.G., Bickers B., Al-Ruwaili J., Aukim-Hastie C., Townsend P.A. Proteomics in prostate cancer biomarker discovery. Exp. Rev. Proteomics 2010, 7:93-102.
104. Barker N., van E J.H., Kuipers J., Kujala P., van den Born M., Cozijnsen M., Haegebarth A., Korving J., Begthel H., Peters P.J., Clevers H. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007, 449:1003-1007.
105. Li L., Clevers H. Coexistence of quiescent and active adult stem cells in mammals. Science 2010, 327:542-545.
106. Silva I.A., Bai S., McLean K., Yang K., Griffith K., Thomas D., Ginestier C., Johnston C., Kueck A., Reynolds R.K., Wicha M.S., Buckanovich R.J. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res. 2011, 71:3991-4001.
107. Kim M.P., Fleming J.B., Wang H., Abbruzzese J.L., Choi W., Kopetz S., McConkey D.J., Evans D.B., Gallick G.E. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One 2011, 6:e20636.
108. Olszewski U., Liedauer R., Ausch C., Thalhammer T., Hamilton G. Overexpression of CYP3A4 in a COLO 205 colon cancer stem cell model in vitro. Cancers 2011, 2011(3):1467-1479.
109. Glazer R.I., Vo D.T., Penalva L.O. Musashi1: an RBP with versatile functions in normal and cancer stem cells. Front Biosci. 2012, 17:54-64.
110. Yan A., Avraham T., Zampell J.C., Haviv Y.S., Weitman E., Mehrara B.J. Adipose-derived stem cells promote lymphangiogenesis in response to VEGF-C stimulation or TGF-β1 inhibition. Future Oncol. 2011, 7:1457-1473.
111. Friedrich J., Siedel C., Ebner R., Kunz-Schughart L.A. Spheroid-based drug screening: considerations and practical approach. Nat. Prot. 2009, 4:309-324.
112. Inch W.R., McCredie J.A., Sutherland R.M. Growth of nodular carcinomas in rodents compared with multi-cell spheroids in tissue culture. Growth 1970, 34:271-282.
113. Sutherland R.M., McCredie J.A., Inch W.R. Growth of multicellular spheroids in tissue culture as a model of nodular carcinomas. J. Nat. Cancer Inst. 1971, 46:113-120.
114. Todaro M., Perez Alea M., Scopelliti A., Medema J.P., Stassi G. IL-4-mediated drug resistance in colon cancer stem cells. Cell Cycle 2008, 7:309-313.
115. Yang X., Zhang S., Pang X., Fan M. Mineralized tissue formation by bone morphogenetic protein-7-transfected pulp stem cells. J. Endod. 2011, 38:170-176.
116. Sodek K.L., Ringuette M.J., Brown T.J. Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. Int. J. Cancer 2009, 124:2060-2070.
117. Hamburger A.W., Salmon S.E. Primary bioassay of human tumor stem cells. Science 1977, 197:461-463.
118. Salmon S.E., Hamburger A.W., Soehnlen B., Durie B.G., Alberts D.S., Moon T.E. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N. Engl. J. Med. 1978, 298:1321-1327.
119. Weiswald L.B., Richon S., Validire P., Briffod M., Lai-Kuen R., Cordelières F.P., Bertrand F., Dargere D., Massonnet G., Marangoni E., Gayet B., Pocard M., Bieche I., Poupon M.F., Bellet D., Dangles-Marie V. Newly characterised ex vivo colospheres as a three-dimensional colon cancer cell model of tumour aggressiveness. Br. J. Cancer 2009, 101:473-482.
120. Dirks P.B. Cancer: stem cells and brain tumors. Nature 2006, 444:687-688.
121. Eramo A., Ricci-Vitiani L., Zeuner A., Pallini R., Lotti F., Sette G., Pilozzi E., Larocca L.M., Peschle C., De Maria R. Chemotherapy resistance of glioblastoma stem cells. Cell Death Different. 2006, 13:1238-1241.
122. Woodward W.A., Chen M.S., Behbod F., Alfaro M.P., Buchholz T.A., Rosen J.M. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc. Natl. Acad. Sci. USA 2007, 104:618-623.
123. Dylla S.J., Beviglia L., Park I.K., Chartier C., Raval J., Ngan L., Pickell K., Aguilar J., Lazetic S., Smith-Berdan S., Clarke M.F., Hoey T., Lewicki J., Gurney A.L. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008, 3:e2428.
124. Bleau A.M., Hambardzumyan D., Ozawa T., Fomchenko E.I., Huse J.T., Brennan C.W., Holland E.C. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009, 4:226-235.
125. Mimeault M., Batra S.K. Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers. Panminerva Med. 2008, 50:3-18.
126. + cells display stem-like features and are spared by cisplatin treatment. Proc. Natl. Acad. Sci. USA 2009, 106:162881-162886.
127. Yu Y., Ramena G., Elble R.C. The role of cancer stem cells in relapse of solid tumors. Front Biosci. (Elite Ed) 2012, 4:1528-1541.
128. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., Nie J., Jonsdottir G.A., Ruotti V., Stewart R., Slukvin I.I., Thomson J.A. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
129. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
130. Takebe N., Harris P.J., Warren R.Q., Ivy S.P. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat. Rev. Clin. Oncol. 2011, 8:97-106.
131. Harris P.J., Speranza G., Dansky Ullmann C. Targeting embryonic signaling pathways in cancer therapy. Expert Opin. Ther. Targets 2012, 16:49-66.
132. Haegebarth A., Clevers H. Wnt signaling, lgr5, and stem cells in the intestine and skin. Am. J. Pathol. 2009, 174:715-721.
133. Curtin J.C., Lorenzu M.V. Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget 2010, 1:563-577.
134. Eayes C.J., Humphries R.K. Acute myeloid leukemia and the Wnt pathway. N. Engl. J. Med. 2010, 362:2326-2327.
135. Subramaniam D., Ramalingam S., Houchen C.W., Anant S. Cancer stem cells: a novel paradigm for cancer prevention and treatment. Mini Rev. Med. Chem. 2010, 10:359-371.
136. Todaro M., Francipane M.G., Medema J.P., Stassi G. Colon cancer stem cells: promise of targeted therapy. Gastroenterology 2010, 138:2151-2162.
137. Chang C.J., Chien Y., Lu K.H., Chang S.C., Chou Y.C., Huang C.S., Chang C.H., Chen K.H., Chang Y.L., Tseng L.M., Song W.S., Wang J.J., Lin J.K., Huang P.I., Lan Y.T. Oct4-related cytokine effects regulate tumorigenic properties of colorectal cancer cells. Biochem. Biophys. Res. Commun. 2011, 415:245-251.
138. Neumann J., Bahr F., Horst D., Kriegl L., Engel J., Mejias Luque R., Gerhard M., Kirchner T., Jung A. SOX2 expression correlates with lymph-node metastases and distant spread in right-sided colon cancer. BMC Cancer 2011, 11:518.
139. Gazouli M., Roubelakis M.G., Theodoropoulos G.E., Papailiou J., Vaiopoulou A., Pappa K.I., Nikiteas N., Anagnou N.P. OCT4 spliced variant OCT4B1 is expressed in human colorectal cancer Mol. Carcinog. 2012, 51:165-173.
140. Saigusa S., Tanaka K., Toiyama Y., Yokoe T., Okugawa Y., Ioue Y., Miki C., Kusunoki M. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann. Surg. Oncol. 2009, 16:3488-3498.
141. Matheu A., Collado M., Wise C., Manterola L., Cekaite L., Tye A.J., Canamero M., Bujanda L., Schedl A., Cheah K.S., Skotheim R.I., Lothe R.A., Lopez de Munain A., Briscoe J., Serrano M., Lovell-Badge R. Oncogenicity of the developmental transcription factor Sox9. Cancer Res. 2012, 72:1301-1315.
142. Brivanlou A.H., Darnell J.E. Signal transduction and the control of gene expression. Science 2002, 295:813-818.
143. Stanley P. Regulation of notch signaling by glycosylation. Curr. Opin. Struct. Biol. 2007, 17:530-535.
144. Najdi R., Holcombe R.F., Waterman M.L. Wnt signaling and colon carcinogenesis: beyond APC. J. Carcinog. 2011, 10:5.
145. Reya T., Clevers H. Wnt signalling in stem cells and cancer. Nature 2005, 434:843-850.
146. Nusse R., Fuerer C., Ching W., Harnish K., Logan C., Zeng A., ten Berge D., Kalani Y. Wnt signaling and stem cell control. Cold Spring Harb. Symp. Quant. Biol. 2008, 73:59-66.
147. Douard R., Moutereau S., Pernet P., Chimingqi M., Allory Y., Manivet P., Conti M., Vaubourdolle M., Cugnenc P.H., Loric S. Sonic Hedgehog-dependent proliferation in a series of patients with colorectal cancer. Surgery 2006, 139:665-670.
148. Mimeault M., Batra S.K. Animal models relevant to human prostate carcinogenesis underlining the critical implication of prostatic stem/progenitor cells. Biochem. Biophys. Acta 1816, 2011:25-37.
149. Chen W., Chen M., Barak L.S. Development of small molecules targeting the Wnt pathway for the treatment of colon cancer: a high-throughput screening approach. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 299:G293-G300.
150. de Sousa E.M., Vermeulen L., Richel D., Medema J.P. Targeting Wnt signaling in colon cancer stem cells. Clin. Cancer Res. 2011, 17:647-653.
151. Li Y., Bavarva J.H., Wang Z., Guo J., Qian C., Thibodeau S.N., Golemisand E.A., Liu W. HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression. Oncogene 2011, 30:2633-2643.
152. Frank N.Y., Schatton T., Frank M.H. The therapeutic promise of the cancer stem cell concept. J. Clin. Invest. 2010, 120:41-50.
153. Kemper K., Rodermond H., Colak S., Grandela C., Medema J.P. Targeting colorectal cancer stem cells with inducible caspase-9. Apoptosis 2012, (January 6).
154. Sun J., Zhang C., Liu G., Liu H., Zhou C., Lu Y., Zhou C., Yuan L., Li X. A novel mouse CD133 binding-peptide screened by phage display inhibits cancer cell motility in vitro. Clin. Exp. Metastasis 2012, 29:185-196.
155. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., Lander E.S. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
156. Lombardo Y., Scopelliti A., Cammareri P., Todaro M., Iovino F., Ricci-Vitiani L., Gulotta G., Dieli F., de Maria R., Stassi G. Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology 2011, 140:297-309.
157. Wang H., Chiou S.H., Chou C.P., Chen Y.C., Huang Y.J., Peng C.A.q. Photothermolysis of glioblastoma stemlike cells targeting by carbon nanotubes conjugated with CD133 monoclonal antibody. Nanomedicine 2011, 7:69-79.
158. Yang Z.F., Ho D.W., Ng M.N., Lau C.K., Yu W.C., Ngai P., Chu P.W., Lam C.T., Poon R.T., Fan S.T. Significance of CD90(+) cancer stem cells in human liver cancer. Cancer Cell 2008, 13:153-166.
159. Kuznetsova L., Chen C., Sun L., Wu X., Pepe A., Veith J.M., Pera P., Bernacki R.J., Ojima I. Syntheses and evaluation of novel fatty acid-second-generation taxoid conjugates a promising anticancer agents. Bioorg. Med. Chem. Lett. 2006, 16:974-977.
160. G.I. Botchkina, I. Ojima, Prostate and colon cancer stem cells as a target for anti-cancer drug development, in: S. Shostak, (Ed.), Cancer Stem Cells Theories and Practice, InTech, 2011, pp. 135-154.
161. Nautiyal J., Kanwar S.S., Yu Y., Majumdar A.P. Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells. J. Mol. Signal 2011, 6:7.
162. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
163. Morrison R., Schleicher S.M., Sun Y., Niermann K.J., Kim S., Spratt D.E., Chung C.H., Lu B. Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J. Oncol. 2011, 2011:1-13.
164. Li F., Sethi G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochem. Biophys. Acta 1805, 2010:167-180.
165. Lin L., Fuchs J., Li C., Olson V., Bekaii-Saab T., Lin J. STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH(+)/CD133(+) stem cell-like human colon cancer cells. Biochem. Biophys. Res. Commun. 2011, 416:246-251.
166. Hendrix M.J., Seftor E.A., Hess A.R., Seftor R.E. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat. Rev. Cancer 2003, 3:411-421.
167. Calabrese C., Poppleton H., Kocak M., Hogg T.L., Fuller C., Hamner B., Oh E.Y., Gaber M.W., Finklestein D., Allen M., Frank A., Bayazitov I.T., Zakharenko S.S., Gajjar A., Davidoff A., Gilbertson R.J. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11:69-82.
168. Hutchinson E. Stem cells: tumour stem cells generate vasculature. Nat. Rev. Cancer 2011, 11:4.
169. Kerbel R.S. Tumor angiogenesis. N. Engl. J. Med. 2008, 358:2039-2049.
170. Pàez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Viñals F., Inoue M., Bergers G., Hanahan D., Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
171. Greenberg J.I., Shields D.J., Barillas S.G., Acevedo L.M., Murphy E., Huang J., Scheppke L., Stockmann C., Johnson R.S., Angle N., Cheresh D.A. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008, 456:809-813.
172. Mimeault M., Batra S.K. Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy. Chinese Med. 2011, 6:31.
173. Goel A., Kunnumakkara A.B., Aggarwal B.B. Curcumin as "Curecumin": from kitchen to clinic. Biochem. Pharmacol. 2008, 75:787-809.
174. Sharma R.A., Euden S.A., Platton S.L., Cooke D.N., Shafayat A., Hewitt H.R., Marczylo T.H., Morgan B., Hemingway D., Plummer S.M., Pirmohamed M., Gescher A.J., Steward W.P. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res. 2004, 10:6847-6854.
175. Yu Y., Kanwar S.S., Patel B.B., Nautiyal J., Sarkar F.H., Majumdar A.P. Elimination of colon cancer stem-like cells by the combination of Curcumin and FOLFOX. Transl. Oncol. 2009, 2:321-328.
176. Patel B.B., Sengupta R., Qazi S., Vachhani H., Yu Y., Rishi A.K., Majumdar A.P. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int. J. Cancer 2008, 122:267-273.
177. Kakarala M., Brenner D.E., Korkaya H., Cheng C., Tazi K., Ginestier C., Liu S., Dontu G., Wicha M.S. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res. Treat. 2010, 122:777-785.
178. Lu K.H., Chen Y.W., Tsai P.H., Tsai M.L., Lee Y.Y., Chiang C.Y., Kao C.L., Chiou S.H., Ku H.H., Lin C.H., Chen Y.J. Evaluation of radiotherapy effect in resveratrol-treated medulloblastoma cancer stem-like cells. Childs Nerv. Syst. 2009, 25:543-550.
179. Gunther S., Ruhe C., Derikito M.G., Bose G., Sauer H., Wartenberg M. Polyphenols prevent cell shedding from mouse mammary cancer spheroids and inhibit cancer cell invasion in confrontation cultures derived from embryonic stem cells. Cancer Lett. 2007, 250:25-35.
180. Majumdar A.P., Banerjee S., Nautiyal J., Patel B.B., Patel V., Du J., Yu Y., Elliott A.A., Levi E., Sarkar F.H. Curcumin synergizes with resveratrol to inhibit colon cancer. Nutr. Cancer 2009, 61:544-553.
181. Qualtrough D., Buda A., Gaffield W., Williams A.C., Paraskeva C. Hedgehog signalling in colorectal tumour cells: induction of apoptosis with cyclopamine treatment. Int. J. Cancer 2004, 110:831-837.
182. Kemper K., Grandela C., Medema J.P. Molecular identification and targeting of colorectal cancer stem cells. Oncotarget 2010, 1:387-395.
183. Vaiopoulos A.G., Kostakis I.D., Koutsilieris M., Papavassiliou A.G. Colorectal cancer stem cells. Stem cells 2012, 30:363-371.
184. Dou J., Gu N. Emerging strategies for the identification and targeting of cancer stem cells. Tumour Riol. 2010, 31:243-253.
185. Sagiv E., Starr A., Rozovski U., Khosravi R., Altevogt P., Wang T., Arber N. Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Res. 2008, 68:2803-2812.
186. Sato T., Vries R.G., Snippert H.J., van de Wetering M., Barker N., Stange D.E., van Es J.H., Abo A., Kujala P., Peters P.J., Clevers H. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009, 459:262-265.
187. Glinka A., Dolde C., Kirsch N., Huang Y.L., Kazanskaya O., Ingelfinger D., Boutros M., Cruciat C.M., Niehrs C. LGR4 and LGR5 are R-spondin receptors mediating Wnt/beta-catenin and Wnt/PCP signalling. EMBO Rep. 2011, 12:1055-1061.
188. Chaudry M.A., Sales K., Ruf P., Lindhofer H., Winslet M.C. EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges. Br. J. Cancer 2007, 96:1013-1019.
189. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., Jacquemier J., Viens P., Kleer C.G., Liu S., Schott A., Hayes D., Birnbaum D., Wicha M.S., Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
190. Rezza A., Skah S., Roche C., Nadjar J., Samarut J., Plateroti M. The overexpression of the putative gut stem cell marker Musashi-1 induces tumorigenesis through Wnt and Notch activation. J. Cell Sci. 2010, 123:3256-3265.
191. Li D., Peng X., Yan D., Tang H., Huang F., Yang Y., Peng Z. Msi-1 is a predictor of survival and a novel therapeutic target in colon cancer. Ann. Surg. Oncol. 2011, 18:2074-2083.
192. Lombardo Y., Scopelliti A., Cammareri P., Todaro M., Iovino F., Ricci-Vitiani L., Gulotta G., Dieli F., de Maria R., Stassi G. Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology 2011, 140(1):297-309.
193. Sokol S.Y. Maintaining embryonic stem cell pluripotency with Wnt signaling. Development 2011, 138:4341-4350.
194. Pang R.W.C., Poon R.T.P. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 2007, 72(supp. 1):30-44.
195. DeAlmeida V.I., Miao L., Ernst J.A., Koeppen H., Polakis P., Rubinfeld B. The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo. Cancer Res. 2007, 67:5371-5379.
196. Suzuki H., Watkins D.N., Jair K.W., Schuebel K.E., Markowitz S.D., Chen W.D., Pretlow T.P., Yang B., Akiyama Y., Van Engeland M., Toyota M., Tokino T., Hinoda Y., Imai K., Herman J.G., Baylin S.B. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet. 2004, 36:417-422.
197. He B., Reguart N., You L., Mazieres J., Xu Z., Lee A.Y., Mikami I., McCormick F., Jablons D.M. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene 2005, 24:3054-3058.
198. Akiri G., Cherian M.M., Vijayakumar S., Liu G., Bafico A., Aaronson S.A. Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma. Oncogene 2009, 28:2163-2172.
199. Bafico A., Liu G., Goldin L., Harris V., Aaronson S.A. An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer cell 2004, 6:497-506.
200. Mao B., Wu W., Davidson G., Marhold J., Li M., Mechler B.M., Delius H., Hoppe D., Stannek P., Walter C., Glinka A., Niehrs C. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 2002, 417:664-667.
201. Bafico A., Liu G., Yaniv A., Gazit A., Aaronson S.A. Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat. Cell Biol. 2001, 3:683-686.
202. Bourhis E., Tam C., Franke Y., Bazan J.F., Ernst J., Hwang J., Costa M., Cochran A.G., Hannoush R.N. Reconstitution of a frizzled8.Wnt3a.LRP6 signaling complex reveals multiple Wnt and Dkk1 binding sites on LRP6. J. Biol. Chem. 2010, 285:9172-9179.
203. Dann C.E., Hsieh J.C., Rattner A., Sharma D., Nathans J., Leahy D.J. Insights into Wnt binding and signalling from the structures of two Frizzled cysteine-rich domains. Nature 2001, 2001:86-90.
204. Zeng X., Huang H., Tamai K., Zhang X., Harada Y., Yokota C., Almeida K., Wang J., Doble B., Woodgett J., Wynshaw-Boris A., Hsieh J.C., He X. Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. Development 2008, 135:367-375.
205. Fre S., Huyghe M., Mourikis P., Robine S., Louvard D., Artavanis-Tsakonas S. Notch signals control the fate of immature progenitor cells in the intestine. Nature 2005, 435:964-968.
206. Miyamoto S., Rosenberg D.W. Role of Notch signaling in colon homeostasis and carcinogenesis. Cancer Sci. 2011, 102:1938-1942.
207. Hoey T., Yen W.C., Axelrod F., Basi J., Donigian L., Dylla S., Fitch-Bruhns M., Lazetic S., Park I.K., Sato A., Satyal S., Wang X.H., Clarke M.F., Lewicki J., Gurney A. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009, 5:168-177.
208. Fan X., Matsui W., Khaki L., Stearns D., Chun J., Li Y.-M., Eberhart C.G. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 2006, 66:7445-7452.
209. Bolós V., Blanco M., Medina V., Aparicio G., Díaz-Prado S., Grande E. Notch signalling in cancer stem cells. Clin. Transl. Oncol. 2009, 11:11-19.
210. Sun P., Xia S., Lal B., Eberhart C.G., Quinones-Hinojosa A., Maciaczyk J., Matsui W., Dimeco F., Piccirillo S.M., Vescovi A.L., Laterra J. DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation. Stem Cells 2009, 27:1473-1486.
211. Akiyoshi T., Nakamura M., Koga K., Nakashima H., Yao T., Tsuneyoshi M., Tanaka M., Katano M. Gli1, downregulated in colorectal cancers, inhibits proliferation of colon cancer cells involving Wnt signalling activation. Gut 2006, 55:991-999.
212. Varnat F., Duquet A., Malerba M., Zbinden M., Mas C., Gervaz P., Altaba A.R.I. Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol. Med. 2009, 1:338-351.
213. Sikandar S.S., Pate K.T., Anderson S., Dizon D., Edwards R.A., Waterman M.L., Lipkin S.M. NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res. 2010, 70:1469-1478.
214. Scales S.J., de Sauvage F.J. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharma. Sci. 2009, 30:303-312.
215. Medina V., Calvo M.B., Díaz-Prado S., Espada J. Hedgehog signalling as a target in cancer stem cells. Clin. Transl. Oncol. 2009, 11:199-207.
216. Hambardzumyan D., Becher O.J., Holland E.C. Cancer stem cells and survival pathways. Cell Cycle 2008, 7:1371-1378.
217. Knapper S., Burnett A.K., Littlewood T., Kell W.J., Agrawal S., Chopra R., Clark R., Levis M.J., Small D. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006, 108:3262-3270.
218. Vellanki S.H., Grabrucker A., Liebau S., Proepper C., Eramo A., Braun V., Boeckers T., Debatin K.M., Fulda S. Small-molecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma. Neoplasia 2009, 11:743-752.
219. Gatti L., Beretta G.L., Cossa G., Zunino F., Perego P. ABC transporters as potential targets for modulation of drug resistance. Mini Rev. Med. Chem. 2009, 9:1102-1112.
220. Estey E., Garcia-Manero G., Ferrajoli A., Faderl S., Verstovsek S., Jones D., Kantarjian H. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006, 107:3469-3473.
221. Miller W.H., Schipper H.M., Lee J.S., Singer J., Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002, 62:3893-3903.
222. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2:48-58.